Genetic Diseases, Inborn

They are caused by genetic mutations affecting the genome during early development. The grounding supports both inherited mutations from a parent's genome and mutations acquired in utero as etiologic sources. Specific disease-causing genes or variant types are not supported here beyond this general genetic basis.

The underlying mechanism is disruption of normal gene function and downstream cellular processes due to pathogenic genomic variation. The supplied literature links genetic disease mechanisms to altered membrane transport, defective ribosome biogenesis and protein synthesis, abnormal ion-channel function, and other gene-specific defects. Genome editing and gene therapy are discussed as ways to modify or replace disease-causing genetic sequences, reflecting the central role of genomic dysfunction.

A family history of a pathogenic mutation can increase risk when the variant is inherited. Exposure to mutagenic or otherwise harmful influences in utero may also increase risk if they lead to acquired fetal mutations. Beyond these broad genetic and prenatal factors, the grounding does not support additional risk factors.

Management is described at the modality level as gene-based therapy, including gene therapy with adeno-associated virus vectors, genome editing approaches such as CRISPR-Cas, TALENs, and zinc-finger nucleases, and RNA interference therapies such as siRNA. The literature also notes approved examples of siRNA and AAV-based therapies for selected inherited diseases, indicating that treatment is increasingly focused on correcting or compensating for the underlying genetic defect. No general conventional drug-class standard of care is supported for the category as a whole.